BridgeBio Pharma Inc [NASDAQ: BBIO] closed the trading session at $27.19.
The stocks have a year to date performance of -32.65 percent and weekly performance of 21.66 percent. The stock has been moved at -2.26 percent over the last six months. The stock has performed 14.05 percent around the most recent 30 days and changed 8.85 percent over the most recent 3-months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
If compared to the average trading volume of 2.09M shares, BBIO reached to a volume of 14421063 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about BridgeBio Pharma Inc [BBIO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BBIO shares is $49.07 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BBIO stock is a recommendation set at 1.33. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Scotiabank have made an estimate for BridgeBio Pharma Inc shares, keeping their opinion on the stock as Sector Outperform, with their previous recommendation back on October 16, 2024. While these analysts kept the previous recommendation, Oppenheimer raised their target price to Perform. The new note on the price target was released on October 03, 2024, representing the official price target for BridgeBio Pharma Inc stock. Previously, the target price had yet another raise to $46, while Piper Sandler analysts kept a Overweight rating on BBIO stock.
The Average True Range (ATR) for BridgeBio Pharma Inc is set at 1.72, with the Price to Sales ratio for BBIO stock in the period of the last 12 months amounting to 23.78.
BBIO stock trade performance evaluation
BridgeBio Pharma Inc [BBIO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 21.66. With this latest performance, BBIO shares gained by 14.05% in over the last four-week period, additionally sinking by -2.26% over the last 6 months – not to mention a drop of -8.08% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BBIO stock in for the last two-week period is set at 62.42, with the RSI for the last a single of trading hit 69.17, and the three-weeks RSI is set at 58.36 for BridgeBio Pharma Inc [BBIO]. The present Moving Average for the last 50 days of trading for this stock 24.98, while it was recorded at 23.89 for the last single week of trading, and 27.22 for the last 200 days.
BridgeBio Pharma Inc [BBIO]: An insightful look at the core fundamentals
BridgeBio Pharma Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.19 and a Current Ratio set at 3.19.
Earnings per share (EPS) analysis for BridgeBio Pharma Inc [BBIO] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BBIO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for BridgeBio Pharma Inc go to 26.80%.
BridgeBio Pharma Inc [BBIO]: Institutional Ownership
There are presently around $94.45%, or 99.84%% of BBIO stock, in the hands of institutional investors. The top three institutional holders of BBIO stocks are: KOHLBERG KRAVIS ROBERTS & CO. L.P. with ownership of 31.06 million shares, which is approximately 16.5582%. VIKING GLOBAL INVESTORS LP, holding 25.12 million shares of the stock with an approximate value of $$636.31 million in BBIO stocks shares; and VIKING GLOBAL INVESTORS LP, currently with $$356.01 million in BBIO stock with ownership which is approximately 7.4924%.
